AN2 Therapeutics, Inc. (ANTX)
5.74
-0.24
(-4.01%)
USD |
NASDAQ |
Sep 09, 12:39
AN2 Therapeutics Shareholders Equity (Quarterly) : 75.92M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 75.92M |
| March 31, 2026 | 81.76M |
| December 31, 2025 | 53.06M |
| September 30, 2025 | 60.38M |
| June 30, 2025 | 68.84M |
| March 31, 2025 | 73.33M |
| December 31, 2024 | 81.85M |
| September 30, 2024 | 87.67M |
| June 30, 2024 | 98.35M |
| March 31, 2024 | 110.60M |
| Date | Value |
|---|---|
| December 31, 2023 | 124.70M |
| September 30, 2023 | 138.97M |
| June 30, 2023 | 87.76M |
| March 31, 2023 | 82.52M |
| December 31, 2022 | 95.37M |
| September 30, 2022 | 105.57M |
| June 30, 2022 | 115.86M |
| March 31, 2022 | 115.41M |
| December 31, 2021 | 61.91M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 1.044M |
| CNBX Pharmaceuticals, Inc. | -2.660M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 562.20M |
| Fulcrum Therapeutics, Inc. | 310.70M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 81.68M |
| Total Liabilities (Quarterly) | 5.755M |
| Current Ratio | 14.32 |